Lawrence K Fung1, Rajneesh Mahajan2, Alixandra Nozzolillo3, Pilar Bernal4, Aaron Krasner5, Booil Jo1, Daniel Coury6, Agnes Whitaker5, Jeremy Veenstra-Vanderweele5, Antonio Y Hardan7. 1. Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California; 2. Kennedy Krieger Institute and Johns Hopkins University School of Medicine, Baltimore, Maryland; 3. Center for Child & Adolescent Health Research and Policy, MassGeneral Hospital for Children, Boston, Massachusetts; 4. Kaiser Permanente Northern California, San Jose, California; 5. New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York; and. 6. Department of Developmental & Behavioral Pediatrics, The Ohio State University, Columbus, Ohio. 7. Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California; hardanay@stanford.edu.
Abstract
BACKGROUND: Autism spectrum disorder (ASD) is increasingly recognized as a public health issue. Irritability and aggression (IA) often negatively affect the lives of people with ASD and their families. Although many medications have been tested for IA in ASDs in randomized controlled trials (RCTs), critical quantitative analyses of these trials are lacking in the literature. OBJECTIVES: To systematically review and quantitatively analyze the efficacy and safety of pharmacologic treatments for IA in youth with ASD. DATA SOURCES: Studies were identified from Medline, PsycINFO, Embase, and review articles. METHODS: Original articles on placebo-controlled RCTs of pharmacologic treatments of IA in youth age 2 to 17 years with ASD were included. Data items included study design, study goals, details of study participants, details of intervention, study results, statistical methods, side effects, and risks of bias. The primary study outcome measure was the effect size of reduction in the Aberrant Behavioral Checklist-Irritability (ABC-I) scores in the medication group, as compared with placebo, in RCTs using parallel groups design. RESULTS: Forty-six RCTs were identified. Compared with placebo, 3 compounds resulted in significant improvement in ABC-I at the end of treatment. Risperidone and aripiprazole were found to be the most effective, with the largest effect sizes. Sedation, extrapyramidal sides effects, and weight gain were assessed quantitatively. CONCLUSIONS: Although risperidone and aripiprazole have the strongest evidence in reducing ABC-I in youth with ASD, a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.
BACKGROUND:Autism spectrum disorder (ASD) is increasingly recognized as a public health issue. Irritability and aggression (IA) often negatively affect the lives of people with ASD and their families. Although many medications have been tested for IA in ASDs in randomized controlled trials (RCTs), critical quantitative analyses of these trials are lacking in the literature. OBJECTIVES: To systematically review and quantitatively analyze the efficacy and safety of pharmacologic treatments for IA in youth with ASD. DATA SOURCES: Studies were identified from Medline, PsycINFO, Embase, and review articles. METHODS: Original articles on placebo-controlled RCTs of pharmacologic treatments of IA in youth age 2 to 17 years with ASD were included. Data items included study design, study goals, details of study participants, details of intervention, study results, statistical methods, side effects, and risks of bias. The primary study outcome measure was the effect size of reduction in the Aberrant Behavioral Checklist-Irritability (ABC-I) scores in the medication group, as compared with placebo, in RCTs using parallel groups design. RESULTS: Forty-six RCTs were identified. Compared with placebo, 3 compounds resulted in significant improvement in ABC-I at the end of treatment. Risperidone and aripiprazole were found to be the most effective, with the largest effect sizes. Sedation, extrapyramidal sides effects, and weight gain were assessed quantitatively. CONCLUSIONS: Although risperidone and aripiprazole have the strongest evidence in reducing ABC-I in youth with ASD, a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.
Authors: Elizabeth Aaron; Alicia Montgomery; Xinguo Ren; Stephen Guter; George Anderson; Ana M D Carneiro; Suma Jacob; Matthew Mosconi; Ghanshyam N Pandey; Edwin Cook; Jeremy Veenstra-VanderWeele Journal: J Autism Dev Disord Date: 2019-06
Authors: Jeremy Veenstra-VanderWeele; Edwin H Cook; Bryan H King; Peter Zarevics; Maryann Cherubini; Karen Walton-Bowen; Mark F Bear; Paul P Wang; Randall L Carpenter Journal: Neuropsychopharmacology Date: 2016-10-17 Impact factor: 7.853
Authors: Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll Journal: World Psychiatry Date: 2020-06 Impact factor: 49.548